Rationally designed multitarget agents against inflammation and pain

S. H. Hwang, A. T. Wecksler, K. Wagner, B. D. Hammock

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Arachidonic acid (ARA) undergoes enzyme-mediated oxidative metabolism, resulting in the formation of a number of biologically active metabolites. For over a century, these biochemical transformations have been the target of numerous pharmacological drugs for inflammation and pain. In particular, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are widely used in the treatment of inflammation and pain. However, gastrointestinal (GI) and cardiovascular adverse effects of NSAIDs and coxibs, and recent findings demonstrating that there are significant risks from the disruption of oxylipin levels when pharmacologically inhibiting a single ARA cascade metabolic pathway, have led to studies involving the simultaneous inhibition of multiple pathways in ARA cascade. These studies suggest that multitarget inhibition represents a new and valuable option to enhance efficacy or reduce side-effects in the treatment of inflammation and pain. This review focuses on the crosstalk within the three pathways of the ARA cascade (cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450)), and summarizes the current and future approaches of multitarget inhibitors for the treatment of eicosanoid driven inflammation and pain.

Original languageEnglish (US)
Pages (from-to)1783-1799
Number of pages17
JournalCurrent Medicinal Chemistry
Volume20
Issue number13
DOIs
StatePublished - Apr 2013
Externally publishedYes

Fingerprint

Arachidonic Acid
Inflammation
Pain
Cyclooxygenase 2 Inhibitors
Anti-Inflammatory Agents
Oxylipins
Pharmaceutical Preparations
Lipoxygenase
Eicosanoids
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Metabolites
Crosstalk
Metabolic Networks and Pathways
Metabolism
Cytochrome P-450 Enzyme System
Therapeutics
Pharmacology
Enzymes
Inhibition (Psychology)

Keywords

  • Cyclooxygenase (COX)
  • Cytochrome P450 (CYP)
  • Dual inhibitors
  • Lipoxygenase (LOX)
  • Multitarget inhibitors
  • Soluble epoxide hydrolase (sEH)

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Rationally designed multitarget agents against inflammation and pain. / Hwang, S. H.; Wecksler, A. T.; Wagner, K.; Hammock, B. D.

In: Current Medicinal Chemistry, Vol. 20, No. 13, 04.2013, p. 1783-1799.

Research output: Contribution to journalArticle

Hwang, SH, Wecksler, AT, Wagner, K & Hammock, BD 2013, 'Rationally designed multitarget agents against inflammation and pain', Current Medicinal Chemistry, vol. 20, no. 13, pp. 1783-1799. https://doi.org/10.2174/0929867311320130013
Hwang, S. H. ; Wecksler, A. T. ; Wagner, K. ; Hammock, B. D. / Rationally designed multitarget agents against inflammation and pain. In: Current Medicinal Chemistry. 2013 ; Vol. 20, No. 13. pp. 1783-1799.
@article{ce1d152b4cf54abfbb68dc2542278802,
title = "Rationally designed multitarget agents against inflammation and pain",
abstract = "Arachidonic acid (ARA) undergoes enzyme-mediated oxidative metabolism, resulting in the formation of a number of biologically active metabolites. For over a century, these biochemical transformations have been the target of numerous pharmacological drugs for inflammation and pain. In particular, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are widely used in the treatment of inflammation and pain. However, gastrointestinal (GI) and cardiovascular adverse effects of NSAIDs and coxibs, and recent findings demonstrating that there are significant risks from the disruption of oxylipin levels when pharmacologically inhibiting a single ARA cascade metabolic pathway, have led to studies involving the simultaneous inhibition of multiple pathways in ARA cascade. These studies suggest that multitarget inhibition represents a new and valuable option to enhance efficacy or reduce side-effects in the treatment of inflammation and pain. This review focuses on the crosstalk within the three pathways of the ARA cascade (cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450)), and summarizes the current and future approaches of multitarget inhibitors for the treatment of eicosanoid driven inflammation and pain.",
keywords = "Cyclooxygenase (COX), Cytochrome P450 (CYP), Dual inhibitors, Lipoxygenase (LOX), Multitarget inhibitors, Soluble epoxide hydrolase (sEH)",
author = "Hwang, {S. H.} and Wecksler, {A. T.} and K. Wagner and Hammock, {B. D.}",
year = "2013",
month = "4",
doi = "10.2174/0929867311320130013",
language = "English (US)",
volume = "20",
pages = "1783--1799",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "13",

}

TY - JOUR

T1 - Rationally designed multitarget agents against inflammation and pain

AU - Hwang, S. H.

AU - Wecksler, A. T.

AU - Wagner, K.

AU - Hammock, B. D.

PY - 2013/4

Y1 - 2013/4

N2 - Arachidonic acid (ARA) undergoes enzyme-mediated oxidative metabolism, resulting in the formation of a number of biologically active metabolites. For over a century, these biochemical transformations have been the target of numerous pharmacological drugs for inflammation and pain. In particular, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are widely used in the treatment of inflammation and pain. However, gastrointestinal (GI) and cardiovascular adverse effects of NSAIDs and coxibs, and recent findings demonstrating that there are significant risks from the disruption of oxylipin levels when pharmacologically inhibiting a single ARA cascade metabolic pathway, have led to studies involving the simultaneous inhibition of multiple pathways in ARA cascade. These studies suggest that multitarget inhibition represents a new and valuable option to enhance efficacy or reduce side-effects in the treatment of inflammation and pain. This review focuses on the crosstalk within the three pathways of the ARA cascade (cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450)), and summarizes the current and future approaches of multitarget inhibitors for the treatment of eicosanoid driven inflammation and pain.

AB - Arachidonic acid (ARA) undergoes enzyme-mediated oxidative metabolism, resulting in the formation of a number of biologically active metabolites. For over a century, these biochemical transformations have been the target of numerous pharmacological drugs for inflammation and pain. In particular, non-steroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) selective inhibitors (coxibs) are widely used in the treatment of inflammation and pain. However, gastrointestinal (GI) and cardiovascular adverse effects of NSAIDs and coxibs, and recent findings demonstrating that there are significant risks from the disruption of oxylipin levels when pharmacologically inhibiting a single ARA cascade metabolic pathway, have led to studies involving the simultaneous inhibition of multiple pathways in ARA cascade. These studies suggest that multitarget inhibition represents a new and valuable option to enhance efficacy or reduce side-effects in the treatment of inflammation and pain. This review focuses on the crosstalk within the three pathways of the ARA cascade (cyclooxygenase (COX), lipoxygenase (LOX), and cytochrome P450 (CYP450)), and summarizes the current and future approaches of multitarget inhibitors for the treatment of eicosanoid driven inflammation and pain.

KW - Cyclooxygenase (COX)

KW - Cytochrome P450 (CYP)

KW - Dual inhibitors

KW - Lipoxygenase (LOX)

KW - Multitarget inhibitors

KW - Soluble epoxide hydrolase (sEH)

UR - http://www.scopus.com/inward/record.url?scp=84877948851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877948851&partnerID=8YFLogxK

U2 - 10.2174/0929867311320130013

DO - 10.2174/0929867311320130013

M3 - Article

C2 - 23410172

AN - SCOPUS:84877948851

VL - 20

SP - 1783

EP - 1799

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 13

ER -